Drug Discovery World

OCTOBER 19, 2022

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .

Drug Delivery 52

Drug Delivery Drugs Drug Delivery Systems Development 52

The Pharma Data

OCTOBER 27, 2020

The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

RNA 52

RNA Drug Delivery Production In-Vitro 52

Druggist

OCTOBER 21, 2020

Overall, oral treatment with drugs cure toenail infections more quickly and effectively than topical treatments (Cochrane, 2017). The main products used for toenail fungus treatment are available in most pharmacies, supermarkets and perhaps with the best range of products found online.

Production 98

Production Containment In-Vitro Sales 98

Drug Discovery World

AUGUST 3, 2022

Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. Here, Bachem explores the science behind this approach. Nanoparticles 6.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc. Forward Looking Statements.

In-Vitro 40

In-Vitro Sales Containment Production 40

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

JANUARY 27, 2021

FDA Investigational New Drug (“IND”)-enabling pharmacology studies. Eurofins Discovery will be conducting the IND-enabling in-vitro preclinical primary pharmacology and safety pharmacology studies on TD-0148A at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs. About BetterLife Pharma: BetterLife Pharma Inc.

In-Vitro 52

In-Vitro Containment Drugs Production 52